A real-world study of Ibrutinib, venetoclax and idelalisib in patients with chronic lymphocytic leukaemia
Latest Information Update: 04 Aug 2021
At a glance
- Drugs Ibrutinib (Primary) ; Idelalisib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 04 Aug 2021 New trial record
- 01 Jul 2021 Results published in the Leukemia and Lymphoma.